Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
04:40pm, Friday, 11'th Nov 2022 Zacks Investment Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
03:20pm, Friday, 11'th Nov 2022 Zacks Investment Research
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
12:47pm, Friday, 11'th Nov 2022
PBYI vs. GMAB: Which Stock Is the Better Value Option?
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing
03:46pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.
Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion
03:43pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemothe
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
04:20pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
04:15pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates
03:08pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
08:07am, Monday, 07'th Nov 2022 Benzinga
Gainers
Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade
Puma Biotechnology, Inc. (PBYI) Q3 2022 Earnings Call Transcript
11:38am, Sunday, 06'th Nov 2022
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - Chief Executive Officer
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
12:48pm, Friday, 04'th Nov 2022
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United S
Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates
08:20pm, Thursday, 03'rd Nov 2022
Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
05:27pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates
04:51pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
04:30pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
